Vision to guide our internal and external development programs.

Scientific Advisory Board (SAB)

homer pearceHomer Pearce, PhD. – Chairman
Homer served in various capacities at Eli Lilly & Company after joining the company in 1979, including Vice President, Cancer Research and Clinical Investigation from 1994 to 2002 and Distinguished Research Fellow, Cancer Research, Lilly Research Laboratories from 2002 to March 2006. He was involved in the development of more than 25 investigational drugs, of which three have resulted in regulatory approvals, including Gemzar® and Alimta®.

Homer was recently named “A Hero of Chemistry” by the American Chemical Society for his role in the discovery and development of the anti-cancer drug Alimta. Homer earned his doctoral degree from Harvard University with Nobel Laureate, E. J. Corey and his bachelor’s degree from Texas A&M University. He is a member of the American Association for Cancer Research, the American Chemical Society and the American Association for the Advancement of Science. He currently serves on several advisory and company boards.

David Broecker — Acting CEO and Member
David is currently serving as board executive and acting CEO to Apexian Pharmaecuticals.  He has served on the board of directors since 2013 and was interim CEO in 2014 to 2015.  David is an experienced business executive with a passion and track record for building organizations and creating value by advancing breakthrough innovation to the marketplace. He currently serves as the Chief Innovation and Collaboration Officer for Purdue Research Foundation. In this role, David is responsible for advancing strategic innovation initiatives targeting corporate partners and key stakeholders.

David is the Founder and CEO of Zorion Medical, a leading medical device company focused on developing and commercializing fully absorbable technology utilizing bio-metals. The first set of applications target peripheral artery disease including arterial dissections, congenital vascular defects in children, and AV fistulas in renal-dialysis patients.

Prior to joining Purdue, David was the Founding President and CEO of the Indiana Biosciences Research Institute in Indianapolis, IN – an independent, non-profit research organization dedicated to discovery science and applied research initially targeting diabetes, cardiometabolic disease, and poor nutrition, inspired by the state’s leading life sciences companies.

David was President and CEO of Alkermes, a publicly traded biotechnology company, leading the organization through significant transformation with the launch of several new products, including Vivitrol – the only long-acting treatment for alcohol and opiate dependence. As both an intra- and entrepreneur, he has led teams in a range of organizations, including multiple start-ups. David started his career at Eli Lilly and Company and for more than 15 years was responsible for supporting the development and commercialization of multiple pharmaceutical, medical device, and diagnostic products.

David received his undergraduate degree from Wabash College where he was a chemistry and mathematics major, graduating summa cum laude and as a member of Phi Beta Kappa.  He completed a graduate degree in chemical engineering from the Massachusetts Institute of Technology and his M.B.A. from the University of Chicago.   He currently serves on the boards of Zorion Medical, Inc., Apexian Pharmaceuticals, and InScope Medical. David is a trustee at Wabash College, chairing the committee on Trusteeship.

David received his undergraduate degree from Wabash College where he was a chemistry and mathematics major, graduating summa cum laude and as a member of Phi Beta Kappa.  He completed a graduate degree in chemical engineering from the Massachusetts Institute of Technology and his M.B.A. from the University of Chicago.   He currently serves on the boards of Apexian Pharmaceuticals, Zorion Medical, Inc., and InScope Medical. David is a trustee at Wabash College, chairing the committee on Trusteeship.

haslanger10x140

Martin Haslanger, PhD. – Member
From 2007 to 2014, Marty served as the CEO leading the company through the discovery of several novel compounds and identification of several potential therapeutic targets for future development.   Prior to Apexian, Marty founded Amphora Discovery Corporation in September 2001.  As President, CEO, he built the company to be a unique discovery engine with multiple projects at the IND-enabling stage. He then served in the Vice Chairman role from January of 2005 until January 2007.

Marty has three decades of pharmaceutical and biotechnology industry experience. Among those were nine years at Eli Lilly from 1992 to 2001, where he served as Executive Director of Research Technologies and President of Sphinx Labs.

Prior to that, he was Director of Cardiovascular and CNS Medicinal Chemistry at the Schering-Plough Research Institute. He began his pharmaceutical career at the Squibb Institute for Medical Research in Princeton, N.J. He led multiple projects from idea to clinical candidate stage at both Squibb and Schering-Plough.

Marty received his Ph.D. in Organic Chemistry at the University of Michigan and completed a postdoctoral fellowship at Harvard University.

Mark KelleyMark R. Kelley, PhD. – Member
Mark is currently the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor, Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology,, Indiana University School of Medicine. He is also the Associate Director, Herman B Wells Center for Pediatric Research and the Associate Director for Basic Science Research at the IU Simon Cancer Center.

Mark completed his postdoctoral Fellowship at The Rockefeller University, New York, NY after earning his M.S. and Ph.D. from Louisiana State University, Baton Rouge, LA in 1984.

Mark holds numerous patents related to the use of DNA repair targets for cancer and has published over 166 articles in peer reviewed journals as well as 28 reviews and book chapters in numerous national and international journals. He also serves on the consulting/scientific boards of several biotechnology companies and has and still serves on various NIH/NCI study sections and Cancer Center review panels. He was chair of the Cancer Etiology Study Section at NIH. He has also reviewed for international agencies. He is a member of American Association for the Advancement of Science, American Association for Cancer Research, Society for Pediatric Research, and American Society of Clinical Oncology.

Mark also serves on the editorial board of Frontiers in Bioscience, Journal of Pharmacology and Experimental Therapeutics, Mutation Research; Molecular and Fundamental Mechanisms (Assoc Editor) and Current Molecular Pharmacology.

messman00x140Richard A. Messmann, M.D., M.H.S., M.Sc. — Chief Medical Officer
Richard is an NCI fellowship-trained medical oncologist with extensive experience in clinical trials in oncology and radiologic imaging.  He served as Deputy Associate Director of the NCI Developmental Therapeutics Program (DTP) managing the division’s personnel, natural products group, biological and pharmaceutical laboratories at Ft. Detrick, MD, as well as being an attending physician for DTP Phase I clinical trials. After government service, Richard was an academic oncologist at Michigan State University, heading the breast cancer team as Principal Investigator for several National Surgical Adjuvant Breast and Bowel Project (NSABP) cooperative group trials.  His pharmaceutical and biotech experience includes being a clinical research physician at Eli Lilly and Company and as Vice President for Medical Affairs at Endocyte, Inc. where his leadership supported a successful IPO for the company (Feb 2011) and a $1B licensing partnership with Merck (March 2012).

Prior to joining Apexian, Richard was the Chief Medical Officer for ProNAi Therapeutics directing development of a BCL2-targeted therapeutic agent, closing on the largest single round of venture capital funding in Michigan’s history, a series D round of $59.5 million before taking the company public in July 2015 raising $158.4 million in the IPO. He has degrees in electrical and computer engineering (B.S., Oakland University), health science and clinical research (M.H.S., Duke University) and biochemistry and medicine (M.Sc. and M.D., Wayne State University). Residency training included anesthesiology and critical care (Georgetown University and University of Michigan) and Internal Medicine (Michigan State University) where he served as chief resident. Richard is a member of the American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology and European Society for Medical Oncology. He is the author of numerous peer-reviewed articles and book chapters.